These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29911104)

  • 21. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
    Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
    Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.
    Horgan D; Metspalu A; Ouillade MC; Athanasiou D; Pasi J; Adjali O; Harrison P; Hermans C; Codacci-Pisanelli G; Koeva J; Szucs T; Cursaru V; Belina I; Bernini C; Zhuang S; McMahon S; Toncheva D; Thum T
    Biomed Hub; 2020; 5(3):130-152. PubMed ID: 33987187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges with advanced therapy medicinal products and how to meet them.
    ; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
    Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to medicines for rare diseases: A European regulatory roadmap for academia.
    Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
    Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
    [No Abstract]   [Full Text] [Related]  

  • 28. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H; Shibatsuji M; Yasuda N
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful development and clinical translation of a novel anterior lamellar artificial cornea.
    Rico-Sánchez L; Garzón I; González-Andrades M; Ruíz-García A; Punzano M; Lizana-Moreno A; Muñoz-Ávila JI; Sánchez-Quevedo MDC; Martínez-Atienza J; Lopez-Navas L; Sanchez-Pernaute R; Oruezabal RI; Medialdea S; Gonzalez-Gallardo MDC; Carmona G; Sanbonmatsu-Gámez S; Perez M; Jimenez P; Cuende N; Campos A; Alaminos M
    J Tissue Eng Regen Med; 2019 Dec; 13(12):2142-2154. PubMed ID: 31373143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework.
    López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T
    Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes.
    Amaouche N; Casaert Salomé H; Collignon O; Santos MR; Ziogas C
    Drug Discov Today; 2018 Oct; 23(10):1801-1805. PubMed ID: 29953957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAT--the new committee for advanced therapies at the European Medicines Agency.
    Celis P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced Therapy Medicinal Products: How to Bring Cell-Based Medicinal Products Successfully to the Market - Report from the CAT-DGTI-GSCN Workshop at the DGTI Annual Meeting 2014.
    Celis P; Ferry N; Hystad M; Schüßler-Lenz M; Doevendans PA; Flory E; Beuneu C; Reischl I; Salmikangas P
    Transfus Med Hemother; 2015 May; 42(3):194-9. PubMed ID: 26195933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review.
    Aguilera-Cobos L; Rosario-Lozano MP; Ponce-Polo A; Blasco-Amaro JA; Epstein D
    Health Policy; 2022 Dec; 126(12):1248-1255. PubMed ID: 36283859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective.
    Pizevska M; Kaeda J; Fritsche E; Elazaly H; Reinke P; Amini L
    Front Med (Lausanne); 2022; 9():757647. PubMed ID: 35186986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATMPs for Cancer Immunotherapy: A Regulatory Overview.
    Galli MC
    Methods Mol Biol; 2016; 1393():1-9. PubMed ID: 27033211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.